Menu
Your Cart

Apostle MagTouch 2000 Nucleic Acid Extraction Automation System (96-well)

Apostle MagTouch 2000 Nucleic Acid Extraction Automation System (96-well)
Secured Shopping
Best security features
Apostle MagTouch 2000 Nucleic Acid Extraction Automation System (96-well)

For fast extraction and purification of nucleic acids from various kinds of biological samples, in 96 well format.

  1. High quality: Equal or better results compared with other brands. 
  2. Lower cost: Guaranteed 30% - 50% less cost than other brands. 
  3. Faster: One button start; Run time is approximately 40 minutes per 96 samples. 
  4. Safer: Integrated with a UV light for unit interior disinfection. 


  • Cat # A201126-96


Documentation:

ManualApostle-MagTouch-2000-manual.pdf

  • This link directs to download the user manual for Apostle MagTouch 2000 Nucleic Acids Isolation Automation System.

Protocol: The system has been utilized by our clients to extract cell-free DNA and/or RNAs from various volumes of liquid samples.  The system is also easily programmable to adapt with various laboratory settings and needs.  Some example protocols are listed below. 


Application Note: Application-Note-Apostle-Viral-RNA-Isolation-System.pdf

  • This links directs to an Application Note on the Apostle COVID-19 Viral RNA Extraction System, applied in the effective detection of SARS-CoV-2 in over 8 million clinical samples by our clients. Using Apostle system, limit of Detection (LoD) of the downstream detection system of our customer is documented at 3.6 NDU/uL published on the FDA website. The sensitivity and specificity is 99.9% and 99.9% at 3 copies/uL, respectively, published on our customer’s website.


Inclusion in US FDA IVD EUA - Molecular Diagnostic Tests for SARS-CoV-2

Apostle RNA extraction method is included in a US FDA EUA authorized SARS-CoV-2 molecular diagnostic test: Fulgent COVID-19 by RT-PCT Test.


More information: Product Data page

$35,000.00
2024年2月,美国MD Anderson癌症中心科学家团队领衔的一项新临床研究发表在Cell子刊 Cancer Cell (影响因子 50.3),建立了临床证据和方法,使用肿瘤cfDNA 甲基化分析可以有效区分小细胞肺癌(SCLC) 亚型,并用于指导SCLC 治疗方案。 在论著的方法学部分,Apostle MiniMax cfDNA 试剂盒被明确列在“关键商业试剂” (Critical commercial assays)表格中,作出自己应用的贡献。Apostle 艾铂图 MiniMax 游离核酸技术不断在国际上得到广泛的应用,迄今,已发表、被引用 Nature 子刊 4篇 ( Nature Medicine X 2, Nature Communications X 2), Science 子刊 1 篇, PNAS 1 篇,各种临床研究60余篇,作者单位来自60余国际领先的医学研究和临床单位。 祝贺此临床研究团队!期待Apostle 艾铂图技术更好地为人类做贡献。